Filing Details
- Accession Number:
- 0000899243-20-030214
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-03 16:05:09
- Reporting Period:
- 2020-11-02
- Accepted Time:
- 2020-11-03 16:05:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779990 | Thomas Michael Henderson | C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-02 | 10,000 | $1.05 | 277,751 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-02 | 9,500 | $38.33 | 268,251 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-02 | 500 | $38.92 | 267,751 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-11-02 | 10,000 | $0.00 | 10,000 | $1.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 28,282 | 2020-05-19 | 2029-09-24 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.
- Represents the weighted average sale price of the shares sold from $37.80 to $38.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
- Represents the weighted average sale price of the shares sold from $38.86 to $38.97 per share.
Billionaire Hedge Funds
